CA-ANOMALI
11.11.2022 00:02:39 CET | Business Wire | Press release
Anomali, the leader in modernizing and scaling security operations by delivering breakthrough levels of visibility and intelligence-driven threat detection and response, today announced that Udit Tibrewal has been appointed to the position of Chief Financial Officer (CFO) and Chief Operating Officer (COO). As Anomali’s CFO and COO, Tibrewal will report directly to Anomali’s CEO, Ahmed Rubaie, leading the company’s global business operations.
“Udit brings decades of experience to Anomali – both in cybersecurity and in building and scaling growth globally. His experience and expertise spanning finance, capital markets, and leading growth-stage companies to an initial public offering will be a tremendous asset to our customers, partners, and investors,” said Ahmed Rubaie, CEO. “Udit’s extensive leadership has been instrumental in helping organizations operate successfully and with the inception of the COO role, we further augment our leadership team and enter 2023 with a higher velocity operating model to help Anomali succeed.”
Tibrewal has more than 25 years of financial leadership and is recognized for his ability to build, scale, and create value. Most recently, Tibrewal was CFO for Arkose Labs, where he was appointed to the firm’s Executive Leadership Team. While at Arkose Labs, he was accountable for all aspects of the company’s global financial operations and led employee engagement, HR and recruiting, and legal and compliance. Recognized for his expertise guiding publicly traded, venture capital-backed and private equity-backed technology companies, he has helped global organizations achieve their strategic objectives. His tenure includes CFO at security and identity company SecureAuth, and SVP Finance of Sitecore, the global leader of context marketing management software. At Sitecore, he was instrumental in the $1.2 billion sale of the company. Additionally, he led the finance organization of ServiceSource, guiding the leading B2B technology platform company to an initial public offering and secondary offering. Tibrewal began his career in public accounting with Big Four firm, PwC.
“I am excited to join the Anomali team as the CFO and newly created role of COO and contribute to the mission of helping organizations modernize their security operations to stop breaches and advanced adversaries,” said Tibrewal. “I look forward to bringing my experience in the security domain and in leading growth stage companies to help Anomali build on its success, drive operational improvements across the company and execute its growth plan.”
For more information, visit: www.anomali.com
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About Anomali
Anomali is the leader in modernizing and scaling security operations, delivering breakthrough levels of security visibility and intelligence-driven threat detection & response. In a world filled with SIEM, SOAR, XDR, the Anomali Platform amplifies visibility, integrating with existing security controls, and enriching them with actionable context to stop the adversaries. Anomali helps customers and partners transform their SOC platform by elevating security efficacy and reducing their cost with automated processes at the heart of everything. The solution is anchored in big-data management and boasts the world’s largest repository of global intelligence that supports native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses, large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, companies, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali. Learn more at www.anomali.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom